BBIO BridgeBio Pharma, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
BBIO Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$77.87
Analyst Target
$89.79
+15.3%
Upside
52W High
$81.33
52W Low
$28.32
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$14.92B
P/E
N/A
ROE
N/A
Profit margin
-225.3%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
75%
Analysis Accuracy
The company exhibits extremely weak fundamental health with a Piotroski F-Score of just 1/9, indicating severe financial distress. Despite explosive revenue growth of 4318% YoY and strong analyst recommendation of 'strong_buy', profitability remains deeply negative with operating and net margins at -112.97% and -225.32% respectively. Insider selling is aggressively bearish, with $56.6M in sales over the last six months and zero buys, contradicting the bullish analyst stance. While liquidity ratios are healthy (Current Ratio: 3.88), the lack of Altman Z-Score and negative valuation metrics suggest high risk and speculative pricing not supported by earnings or cash flow.
Key Strengths
Exceptional year-over-year revenue growth of 4318.00% indicates strong commercial or pipeline momentum
High gross margin of 95.78% suggests scalable business model and pricing power
Strong analyst consensus with 'strong_buy' rating from 19 analysts
Healthy liquidity position with Current Ratio of 3.88 and Quick Ratio of 3.52
Recent positive EPS trends showing YoY improvement of +33.3% and Q/Q growth of +24.2%
Key Risks
Critically low Piotroski F-Score of 1/9 signals severe financial weakness and poor earnings quality
Massive insider selling: $56.6M in sales over 6 months with no insider buying, indicating lack of confidence from executives
Negative profitability across all metrics: ROA at -43.48%, Operating Margin at -112.97%, and Profit Margin at -225.32%
Valuation metrics are deeply negative: Forward P/E of -43.91 and Price/Book of -7.76, indicating no earnings or book value support
Absence of Altman Z-Score prevents bankruptcy risk assessment, but negative equity and earnings suggest potential distress
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
28
Weak
10
75
40
15
0
AI Verdict
High-risk speculative biotech with unsustainable fundamentals despite growth
Key drivers: Piotroski F-Score of 1 severely penalizes health, Insider selling contradicts analyst optimism, Negative profitability and valuation metrics, Exceptional revenue growth provides upside potential, Liquidity buffers reduce near-term solvency risk
Confidence
78%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 42.18 may be justified in high-growth biotech
Watchpoints
- Forward P/E of -43.91 indicates no earnings
- Price/Book of -7.76 shows negative equity
- Graham Number is $None — no defensive value
Future
75/100
Ref Growth rates
Positives
- Revenue Growth (YoY): 4318.00%
- EPS YoY Growth: +33.3%
- EPS Q/Q Growth: +24.2%
Watchpoints
- Earnings growth unstable and negative in absolute terms
- No Forward EBITDA or cash flow guidance
Past
40/100
Ref Historical trends
Positives
- Recent quarters show improving EPS trends
- Some earnings beats in history (e.g., +77% in Q1 2024)
Watchpoints
- Average earnings surprise over last 4 quarters: -16.17%
- Consistent negative earnings and misses since 2020
- Only 2 out of last 4 quarters beat estimates
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current Ratio: 3.88
- Quick Ratio: 3.52
Watchpoints
- Piotroski F-Score: 1/9 (Weak)
- Altman Z-Score: None (Unassessable, but likely distressed)
- ROA: -43.48%
- Debt/Equity: N/A (likely negative equity)
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength: 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$77.87
Analyst Target
$89.79
Upside/Downside
+15.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BBIO and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BBIO
BridgeBio Pharma, Inc.
Primary
|
+18.4% | +720.5% | +110.0% | +68.2% | +1.8% | +2.1% |
|
ASND
Ascendis Pharma A/S
Peer
|
+48.1% | +92.3% | +84.6% | +40.6% | +10.6% | +14.4% |
|
MRNA
Moderna, Inc.
Peer
|
-66.5% | -78.1% | +23.9% | +33.8% | +37.1% | +21.9% |
|
NBIX
Neurocrine Biosciences, Inc.
Peer
|
+21.7% | +22.3% | -6.7% | +0.3% | -6.6% | -2.5% |
|
HOLX
Hologic, Inc.
Peer
|
-1.3% | -5.6% | +7.2% | +17.2% | +0.1% | +0.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-43.91
PEG Ratio
N/A
P/B Ratio
-7.76
P/S Ratio
42.18
EV/Revenue
45.88
EV/EBITDA
-28.32
Market Cap
$14.92B
Profitability
Profit margins and return metrics
Profit Margin
-225.32%
Operating Margin
-112.97%
Gross Margin
95.78%
ROE
N/A
ROA
-43.48%
Growth
Revenue and earnings growth rates
Revenue Growth
+4318.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
3.88
Strong
Quick Ratio
3.52
Excellent
Cash/Share
$3.35
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-19
$N/A
2025-10-29
$-0.72
+7.7% surprise
2025-08-05
$-0.95
-57.1% surprise
2025-04-29
$-0.99
+0.9% surprise
Healthcare Sector Comparison
Comparing BBIO against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Profit Margin
-225.32%
This Stock
vs
-20.78%
Sector Avg
+984.5%
(Superior)
Revenue Growth
4318.0%
This Stock
vs
137.39%
Sector Avg
+3042.8%
(Fast Growth)
Current Ratio
3.88
This Stock
vs
3.36
Sector Avg
+15.3%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BBIO
BridgeBio Pharma, Inc.
|
BEARISH | $14.92B | - | -% | -225.3% | $77.87 | |
|
ASND
Ascendis Pharma A/S
|
NEUTRAL | $14.38B | - | -% | -36.0% | $235.39 | |
|
MRNA
Moderna, Inc.
|
BEARISH | $16.34B | - | -29.3% | -139.6% | $41.83 | |
|
NBIX
Neurocrine Biosciences, Inc.
|
NEUTRAL | $13.2B | 31.6 | 15.0% | 16.0% | $132.39 | |
|
HOLX
Hologic, Inc.
|
NEUTRAL | $16.73B | 30.11 | 11.1% | 13.8% | $74.98 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-09 | KUMAR NEIL | Chief Executive Officer | Sale | 80,000 | $6,043,168 |
| 2025-12-15 | KUMAR NEIL | Chief Executive Officer | Sale | 30,011 | $2,239,902 |
| 2025-12-12 | KUMAR NEIL | Chief Executive Officer | Stock Award | 60,975 | - |
| 2025-12-08 | APULI MARICEL | Officer | Sale | 2,000 | $148,520 |
| 2025-12-05 | KUMAR NEIL | Chief Executive Officer | Sale | 80,000 | $5,908,476 |
| 2025-11-20 | KUMAR NEIL | Chief Executive Officer | Sale | 26,156 | $1,722,224 |
| 2025-11-18 | LO ANDREW W. | Director | Sale | 95,599 | $6,319,662 |
| 2025-11-17 | SCOTT RANDAL W | Director | Sale | 10,000 | $666,465 |
| 2025-11-17 | TRIMARCHI THOMAS | President | Sale | 16,934 | $1,125,404 |
| 2025-11-17 | SCOTT RANDAL W | Director | Option Exercise | 10,000 | $167,500 |
| 2025-11-14 | KUMAR NEIL | Chief Executive Officer | Stock Award | 64,697 | - |
| 2025-11-12 | VALANTINE HANNAH A. | Director | Sale | 25,484 | $1,683,728 |
| 2025-11-12 | VALANTINE HANNAH A. | Director | Option Exercise | 25,484 | $1,234,700 |
| 2025-11-07 | KUMAR NEIL | Chief Executive Officer | Sale | 80,000 | $4,983,111 |
| 2025-11-06 | DANIELS RONALD J | Director | Sale | 61,031 | $3,888,999 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
19 analysts
Wells Fargo
2026-01-20
Overweight
Overweight
Truist Securities
2026-01-08
Buy
Buy
Morgan Stanley
2026-01-06
Overweight
Leerink Partners
2025-12-15
Outperform
Outperform
Bernstein
2025-12-11
Outperform
Wells Fargo
2025-11-11
Overweight
Overweight
JP Morgan
2025-11-07
Overweight
Overweight
HC Wainwright & Co.
2025-11-03
Buy
Buy
Goldman Sachs
2025-10-31
Buy
Buy
TD Cowen
2025-10-30
Buy
Buy
Past News Coverage
Recent headlines mentioning BBIO from our newsroom.
Newest → oldest
No matching news yet.